A series of five fluorinated chalcones (E)-3-(2′-ethoxyphenyl)-1-(4-Fluoro-2-hydroxyphenyl)prop-2-en-1-one (4), (E)-3-(3′,4′-
Introduction
The rapid emergence of antibiotic resistance has become a notorious, global problem and fluorinated organic compounds have been considered one of the groups of compounds that are intriguing for the development of pharmaceuticals for this tremendous public health concern.
Fluoro-organic compounds have inherent biologically activity and the introduction of fluorine into a biological active compound improves its pharmacological properties. Hence, much effort is being made to develop more general and efficient approaches for introducing fluorine atom(s) or fluoroalkyl group(s) into organic compounds [1] . The pharmacological superiority of fluorinated compounds over their non-fluorinated analogues may be due to C-F bond which is ordinarily stronger than C-H bond and the strength of C-F bond conveys stability to fluorine compounds hence are likely to be recalcitrant in the environment or may be partially metabolised to a more toxic metabolite. Also, the introduction of fluorine confers lipophilicity [1, 2] . These factors are operative singly or sometimes cooperatively to affect the pharmacological properties of the fluorinated compounds [3] . Several studies revealed that fluorinated compounds are a significant class of compounds in medicinal and pharmaceutical therapy, for example, 5-fluorouracil and 5-fluoro-2-deoxyuridine have been used in the treatment of cancer [4, 5] while ciprofloxacin, a mono-fluoro aromatic compound, commonly used as antibiotics, is active against both Gram-positive and Gram-negative bacteria [6] .
A number of fluorinated chalcones have been synthesized and evaluated for their biological activities. Fluorine groups, either as aryl fluoro or trifluoromethyl have been previously attached on their respective precursors. For example, some derivatives of 4′-fluoro-4-hydroxychalcone have been shown to possess anti-inflammatory, antioxidant and analgesic property [7, 8] . Aryl fluorinated derivatives of 2,4-dihydroxyl-3′,4′-dimethoxy-chalcone were shown to possess anti-peroxidation, anti-inflammation and antihypersensitivity properties [9] and trifluoromethyl methoxy chalcone was evaluated as an excellent antimalarial compound [10] . Several studies have shown that derivatives of polyfluorinated chalcones are more active than their monofluorinated counterparts. For instance, various derivatives of aryl difluoro chalcones have been shown to be more effectives against human pancreatic cancer cells and breast cancer cells than the monosubstituted and hydroxylated derivatives in a pharmacological comparative study [11] . A series of (E)-1-(4-fluorophenyl)chalcones were evaluated and found to possess antibacterial activities against E. coli and P. aeruginosa and, antifungal activity against A. niger [12] .
In an effort to develop potent fluorinated antibiotic compounds to stem the effects of drug resistance, the present study was conducted to synthesize various derivatives of 4-fluoro-2-hydroxychalcones (4-Fluoro-2-hydroxyphenyl) prop-2-en-1-one) and screen them for their antibacterial activities.
Experimental

Synthesis
Five derivatives of 4-fluoro-2-hydroxychalcone (4, 5, 6, 7, 8) were synthesized by refluxing 4-fluoro-2-hydroxyacetophenone (3) with each of 4-(N,N-diethylamino)benzaldehyde, 2-ethoxybenzaldehyde, 3,4-diethoxybenzaldehyde, 2,3-dihydrobenzofuran-5-carbaldehyde and 3,5-Bis[trifluoromethyl] benzaldehyde respectively.
Chromatographic technique using TLC aluminum sheet pre-coated plate from Merck (silica gel 60 F 254 , layer thickness 0.2 mm, 20% ethyl acetate in hexane) was employed to monitor the progress of the reaction. The plate was also used for analytical TLC and to determine the retardation factor (R f ) values. Spots were viewed at 254 nm and 366 nm (Model UVGL-58).
The compounds were purified using open column chromatography on silica gel 60 from Merck (60-120 mesh). The columns were packed wet with n-hexane and the compounds were dissolved in dichloromethane and dry loaded. n-Hexane:ethyl acetate (9:1) solvent mixture was used to elute the mixture through the column.
NMR spectra of the compounds were measured using a Proton decoupled Bruker 400 MHz spectrometer with internal standard residual resonance signal of deuterated chloroform and dimethylsulphoxide (DMSO), for those insoluble in CDCl 3 , as specified in the spectra. All spectra measurements were carried out at room temperature.
The mass spectra of the compounds were measured using an Agilent technology GC-MS 7890A coupled with MSD 5975C, with GC ALS as injection source. The recording was carried out under these conditions: Injection volume (2 µL), over maximum temperature of 325 °C and equilibrium time of 0.25 min. Column size 30 m × 320 µm × 0.25 µm, initial temperature of 110 °C and flow rate of 1.6282 ml/ min. The samples were derivatized using N-methylbis[trifluoroacetamide] in methanol as solvent.
All the solid products were purified by recrystallization from 98% ethanol. The melting point (uncorrected) were recorded using a Stuart SMP40 automated melting point apparatus (ramp rate 5 °C per minute, start temperature 50 °C and automatic stop).
The IR spectra of finely ground compounds were recorded on a FTIR-ATR spectrometer (Cary 630), using transmittance method.
General procedure for the synthesis of E-1-(4-flouro-2-hydroxyphenyl)-3-(substituted phenyl)-2-propen-1-one
A mixture of the appropriate benzaldehyde derivatives (5 mmol) and 4-fluoro-2-hydroxyacetophenones (1) (5 mmol) in 98% ethanol (20 mL) was stirred in a round bottom flask and 50% NaOH solution (2 mL) was added gradually with constant stirring under reflux for about 5 h. The reaction mixture was allowed to cool to room temperature, then poured over crushed ice, acidified with 10% HCl until the reaction mixture was slightly acidic to wet litmus paper and allowed to stand overnight in an ice bath. The product formed was filtered using a vacuum pump, then washed several times with cold distilled water, dried and recrystallized from absolute ethanol [7, 13] . 
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Antibacterial evaluation
The antibacterial activities of the compounds were evaluated using the following organisms, 
Preparation of culture media and compounds
Mueller-Hinton agar (Oxoid, England) was used as the growth medium for the microbes. The dehydrated bacteriological culture media was weighed (36 g) and dissolved in distilled water (100 mL) according to the manufacturer's specification. The resultant suspension was dispensed into clean conical flask and sterilized at 121 °C for 15 min in an Adelphi bench autoclave and then poured into previously sterilized petri dishes. The plates were allowed to cool and solidify, initial concentration of each of the compounds (200 µg/mL) was prepared by weighing the compound (0.002 g) and dissolving in DMSO (10 mL) to obtain the stock solution [14] .
Antimicrobial profile (zone of inhibition)
The antibacterial screening was carried out using the agar diffusion method [14] . The prepared medium was seeded with standard inoculums (0.1 mL) of the micro-organism. The inoculums were then spread evenly using a sterilized swab over the surface of the medium, seeded plates were allowed to dry at 37 °C for 30 min inside an incubator (GENLAB WIDNES ENGLAND, model: EIS). A standard cork borer, 6 mm in diameter was used to cut a well at the centre of each seeded medium used and 0.1 mL of the solution of the compounds (200 µg/mL) was then introduced into each hole on the surface of the medium. The plates were then incubated at 37 °C for 24 h, after which the plates were observed for zone of inhibition at growth. The zones of inhibition were measured with a transparent ruler and the results recorded in millimeter. Ciprofloxacin (10 µg/mL) was used as the standard drug.
Determination of minimum inhibitory concentration (MIC)
MIC was carried out using broth dilution method [15, 16] . Mueller-Hinton broth (Oxoid, England) was prepared and 10 mL was dispensed into test tubes and sterilized at 121 °C for 15 min, the broth was allowed to cool. Mac-Farland's turbidity standard scale number 0.5 was prepared to give a turbid solution. Normal saline was prepared and 10 ml was dispensed into sterilized test tubes and the test microorganism was inoculated and incubated at 37 °C for 6 h. After incubation, dilution of the micro-organism in normal saline was done until the turbidity matched that of the MacFarland scale by visual comparison, at this point the test micro-organisms have a concentration of about 1.5 × 10 8 cfu/mL. Two-fold serial dilution of the compound in the sterilized broth was done to obtain the concentration of 200 µg/mL, 100 µg/mL, 50 µg/mL, 25 µg/mL, and 12.5 µg/mL respectively. The initial concentration was obtained by dissolving 0.002 g of the compound in 10 mL of the sterile broth. From the suspension of the micro-organism in normal saline, 0.1 mL was inoculated into the different concentrations of the compound in the Mueller-Hinton broth. The broths were then incubated at 37 °C for 24 h, after which the test tubes were observed for turbidity which indicates growth of the microorganism. The test tube with lowest concentration of the compound which showed no turbidity was recorded as the minimum inhibitory concentration (MIC).
Determination of minimum bactericidal concentration (MBC)
MBC was carried out to check whether the test microbes were killed or only their growth were inhibited. Mueller-Hinton agar (Oxoid, England) was prepared according to manufacturer's instruction, sterilized at 121 °C for 15 min. It was poured into sterilized petri-dishes. The plates were allowed to cool and solidify. The content of the MIC test tubes in the serial dilution were sub-cultured on to the prepared plates. The plates were then incubated at 37 °C for 24 h, after which the plates were observed for colony growth. The MBC was the plate with lowest concentration of the compound without colony growth [15, 16] .
Results and discussion
Synthesis of E-1-(2-hydroxylphenyl) prop -2-en-1-one derivatives
An illustration of the synthetic approach to the prepared compounds is illustrated in Scheme 1. The compounds were yellow in colour except for compound (8) which was red in colour which may be due to increased conjugation and the strong complementary electronic effect of the amino substituent at the para position of the B-ring. Product yields range from 55 to 84% (Table 1 ). The highest yield was obtained for compound (6) containing 2,3-dihydrobenzofuran moiety while compound (7) gave the least yield. The poor yield of the later might be due to the bulky nature of trifluoromethyl substituents at the meta positions of the ring B that may hinder proper condensation of the reactants [13] . In general, the rate of reaction decreased in the order of 2,3-dihydrobenzofuran > 2-ethoxyphenyl > 3,4-diethoxyphenyl > 4-(diethylamino)phenyl > 3,5-bis[trifluoromethyl]phenyl with regard to substituents on the B-ring. Table 2 ). The delocalization of electrons among the three carbon atoms of the chromophore resulted in the β-carbon resonance being more deshielded than α-carbon.
The use of proton decoupled 13 C spectrometer for the analyses of the compounds resulted in the doublet splitting of fluorinated aromatic carbon (C-4) peaks and that of all the carbons at ortho (C-3 and C-5) and meta (C-6) positions relative to the fluorine atom on the ring (Fig. 1) with the (Table 3 ). This is similar to values obtained in other studies (for Aryl C-F δ = 163.7 ppm, J = 255.3 Hz; C-3 and C-5, δ = 105.0 ppm, J = 22.1 Hz) and C-6, δ = 130.6 ppm, J = 8.8 Hz) [17] . For 1 H NMR spectra, the two olefinic trans protons of the chromophores were characterized by the presence of large coupling constants ranged from 15 to 19 Hz, which is expected for trans coupled olefinic protons.
The FTIR spectra showed broad intense peaks mostly at 3414 cm −1 for hydrogen bonded hydroxyl groups. The bands ranging from 1636 to 1654 cm −1 was observed for C=O str , 3000 cm −1 for aromatic C-H str , 2914 and 2996 cm −1 aliphatic C-H str and 1490 and 1520 cm −1 for C α = C β stretching of the chromophores. The m/z values of the compounds were equivalent to their respective theoretical molecular weights which confirmed the products. 
Antibacterial evaluation
All the compounds showed varying degrees of antibacterial activities against both Gram-positive and Gram-negative species based on the observed zones of inhibition which ranged from 20 to 28 mm (Table 4 ). The compounds that showed positive activity were further tested to determine their minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) ( Table 5 ). The activities of the compounds compared favourably with that of the standard drug (ciprofloxacin) and in some cases where the microbes were resistant to the standard drug, they were sensitive to some of the prepared compounds. For instance, all the compounds, except compound (6) containing the 3′,5′-Bis[trifluoromethyl]phenyl moiety, have a broad-spectrum activity against MRSA with zone of inhibition ranging from 23 to 28 mm while the standard drug exhibited no potency against this microbe. Compounds (4), (5) and (8) containing the 4′-(diethylamino), 2′-ethoxyl and 3′,4′-diethoxyl substituents respectively on the B-ring showed remarkable activity against C. ulcerans whereas standard drug was inactive against this microbe. P. aeruginosa was resistant to standard drug as well as all the compounds with the exception of compound (8) containing the 4′-(diethylamino)phenyl moiety. The activity of this compound against P. aeruginosa made it a potential drug against this multi-drug resistance species. The MIC of all the compounds were between 25 and 50 µg/mL while MBC ranged from 50 to 200 µg/mL. The activities of the compounds against the tested microbes were observed to decrease in order of compound containing 4′-(diethylamino)phenyl > 2′-ethoxyphenyl > 3′,4′-diethoxyphenyl > 2,3-dihydrobenzofuran > 3,5-Bis[trifluoromethyl] phenyl moieties. This observation might be due to electronic effect of substituents on the B-ring with compound (8) containing the 4′-(diethylamino) substituent being a strong electron releasing group and at the para position of the ring. This is the most active compound against the bacteria strains. The combined effects of the fluorine atom on the A-ring and the electron releasing group on the B-ring in (8) which also has the added advantage of forming an 50  100  --50  100  25  50  50  100 ammonium ion in physiological pH conferring a positive charge on the compound could enable it to easily penetrate the negatively charged bacterial cell wall especially of hardy Gram-negative bacteria. The negative inductive effect of the trifluoromethyl substituent in compound (6) might be responsible for its lower activity.
(E)-3-(4-fluorophenyl)chalcones have been reported to show antitubercular and antibacterial activities against S. aureus and antifungal activity against C. albicans. The research further revealed that fluorinated chalcones with fluoro-substitution in position 2 and or position 5 of its B ring showed higher antibacterial potency against S. aureus, S. pyogenes, E. feacalis, E. coli, P. aeruginosa and antifungal activity against C. albicans, C. glabrata and C. parapsilosis. However, the presence of hydroxyl group on the A ring decreases the antitubercular activity of theses fluorinated chalcones [18] . Also, fluorinated chalcones-1,2,3-triazoles conjugates have been reported to show significant activity against some bacterial and fungal strains [19] . Several other reports on biological evaluation of fluorinated chalcones revealed some of its pharmacological importance. For instance, (E)-1-(2-hydroxyphenyl)-3-(4-fluorophenyl)chalcones was shown to possess antibacterial activity against E. coli, B. pumilis and B subtilis and, antifungal activity against A. niger [20] . These findings on the potency, against various pathogens, of the synthesized chalcones are similar to the observations reported in the cited literatures, Apart from the reported effect of fluoro groups on biological activitiy, other reports suggested that the α,β-unsaturated carbonyl group in chalcones are responsible for their antimicrobial activity [21] and the presence of more than one electron withdrawing group on B-ring of the chalcone skeleton might reduce this observed antimicrobial activity [22] .
Conclusion
This work reports the synthesis, characterization and antibacterial activities of five derivatives of (E)-1-(4-fluoro-2-hydroxylphenyl)chalcone with 4′-(diethylamino)phenyl, 2′-ethoxyphenyl, 3′,4′-diethoxyphenyl, 2′,3′-dihydrobenzofuran and 3′,5′-Bis[trifluoromethyl]phenyl moieties as the B-ring. These compounds were synthesized in good yield by a modified Claisen-Schmidt condensation and the structures characterized using NMR and GCMS spectral analysis. The fluorinated chalcones were then evaluated for antibacterial activities against MRSA, VRE, Staphylococcus aureus, Streptococcus pyrogenes, Streptococcus feacalis (Gram-positive) and Escherichia coli, Salmonella typhi, Corynebacterium ulcerans, Proteus mirabilis, Pseudomonas aeruginosa (Gram-negative). The antibacterial activity of the compounds compared favourably with that of ciprofloxacin and appeared to have broad spectrum activity. Compounds containing the electron releasing moieties of 4′-(diethylamino)phenyl, 2′-ethoxyphenyl and 3′,4′-diethoxyphenyl were found to be the most potent in that order while the compound containing the strong electron withdrawing moiety of 3′,5′-Bis[trifluoromethyl]phenyl was found to be the least potent especially against Gram-negative bacterial strain. The results suggest that the synthesized compounds, especially the compound with the 4′-(diethylamino) substituent, were better, and could be used, after in vivo and clinical tests and establishing their safety profiles, to supplement or even replace current drug therapies. Especially for drugs which pathogenic microorganisms have or are developing resistance, for example MRSA and P. aeruginosa which are responsible for life-threatening, and other nosocomial infections such as life-threatening diseases for example pneumonia, meningitis, toxic shock syndrome, sepsis, urinary tract infections (UTIs), and bacteremia.
